

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):	Thompson, <i>et al.</i>	Attorney Docket No.:	05569.0007.CPUS02
App. No.:	10/625,307	Title:	SPECIFIC BINDING MEMBERS FOR HUMAN TRANSFORMING GROWTH FACTOR BETA: MATERIALS AND METHODS
Conf. No.:	2383	Art Unit:	1644
Filing Date:	July 23, 2003	Examiner:	Gambel, Phillip

**SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT PURSUANT TO 37 C.F.R. §§ 1.56, 1.97 and 1.98**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In compliance with 37 C.F.R. § 1.97 and the continuing duty of disclosure under 37 C.F.R. § 1.56, Applicants call to the attention of the Examiner the references listed on the attached Forms PTO/SB/08A and PTO/SB/08B. It is respectfully requested that this Information Disclosure Statement be entered and the document listed on attached Forms PTO/SB/08B be considered by the Examiner and made of record.

The references on attached Forms PTO/SB/08A and PTO/SB/08B were submitted during prosecution of U.S. Patent Application Nos.: 08/571,755 and 09/054,847, the parent applications from which the instant application claims priority under 35 U.S.C. § 120. Specifically, references A1-A10, B1-B15 and C1-C32 were submitted during prosecution of 08/571,755 and considered by the Examiner. References A11-A17, B15-B37 and C33-C107 were submitted during prosecution of 09/054,847 and were considered by the Examiner. Copies of the non-patent literature cited on Form PTO/SB/08B which were submitted to the Office in the parent applications are not provided, in accordance with 37 C.F.R. § 1.98(d). Reference C108 was not submitted during the prosecution of either of the parent applications and therefore a copy of this reference is submitted herewith.

In accordance with 37 C.F.R. § 1.97(g), this Information Disclosure Statement is not to be construed as a representation that a search has been made. In accordance with 37 C.F.R. § 1.97(h), this

Information Disclosure Statement is not to be construed as an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

This Information Disclosure Statement is being filed prior to the receipt of a final action under 37 C.F.R. § 1.113, a notice of allowance under 37C.F.R. § 1.311, or an action that otherwise closes prosecution in this application. The Commissioner is hereby authorized to deduct the fee of \$180.00 set forth in §1.17(p) from Howrey LLP Deposit Account 08-3038 referencing the above-identified attorney docket number, and hence this Information Disclosure Statement is believed to be timely filed in accordance with 37 C.F.R. §1.97(c)(2). No other fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any additional fees under 37 C.F.R. §§1.16 to 1.21 be deemed necessary for any reasons relating to this document, the Commissioner is hereby authorized to deduct the fees from the above-identified Deposit Account.

Respectfully submitted,

HOWREY LLP

Dated: September 20, 2007

By: David W. Clough/  
David W. Clough, Ph.D.  
Registration No.: 36,107  
Customer No.: 22930

HOWREY LLP  
321 N. Clark Street, Suite 3400  
Chicago, IL 60661  
(312) 595-1239 (main)  
(312) 595-1408 (direct)  
(312) 595-2250 (fax)